MARKET

ATNM

ATNM

Actinium Pharmac
AMEX
1.580
+0.150
+10.49%
After Hours: 1.590 +0.01 +0.63% 19:49 07/09 EDT
OPEN
1.450
PREV CLOSE
1.430
HIGH
1.580
LOW
1.450
VOLUME
267.26K
TURNOVER
--
52 WEEK HIGH
8.64
52 WEEK LOW
1.029
MARKET CAP
49.29M
P/E (TTM)
-1.0723
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ATNM last week (0630-0704)?
Weekly Report · 2d ago
Weekly Report: what happened at ATNM last week (0623-0627)?
Weekly Report · 06/30 09:47
Promising Preclinical Results for ATNM-400 Drive Buy Rating for Actinium Pharmaceuticals
TipRanks · 06/25 17:15
Positive Outlook on Actinium Pharmaceuticals: Promising Preclinical Data and Strong Financial Position Drive Buy Rating
TipRanks · 06/24 10:26
Actinium highlights expanded data set for ATNM-400 in prostate cancer
TipRanks · 06/23 17:33
Actinium Pharma Reports New Preclinical Data From Non-PSMA Targeting Radiotherapy Prostate Cancer Candidate ATNM-400, At SNMMI Annual Meeting
Benzinga · 06/23 15:33
Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting
PR Newswire · 06/23 15:30
Weekly Report: what happened at ATNM last week (0616-0620)?
Weekly Report · 06/23 09:45
More
About ATNM
Actinium Pharmaceuticals, Inc. specializes in the development of targeted radiotherapies. The Company is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The Company is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.

Webull offers Actinium Pharmaceuticals Inc stock information, including AMEX: ATNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATNM stock methods without spending real money on the virtual paper trading platform.